Which GLP-1 Will Insurance Actually Cover?

The question people ask is which GLP-1 is best. The question that determines what they actually get is which one their plan will approve — and those have different answers. Coverage in this category follows product and indication, not effectiveness, and understanding that distinction is worth more than any comparison chart.

How We Assessed These

What actually drives an approval decision, roughly in order of weight.

The Product Trap

This causes more denials than anything else. Ozempic and Wegovy are both semaglutide; Mounjaro and Zepbound are both tirzepatide. Within each pair, one carries a diabetes indication and one carries a weight management indication.

Coverage follows the product, not the ingredient. Humana, for example, covers Mounjaro for type 2 diabetes with prior authorization but not weight loss, and Mounjaro is excluded from the 2026 Medicare GLP-1 Bridge — while Zepbound is the weight-loss tirzepatide product. Requesting the wrong product for your indication produces a denial that looks like a coverage refusal but is really a paperwork mismatch.

Build the Comorbidity Case

Coverage criteria commonly require a BMI threshold plus a weight-related condition. The ones that qualify are broader than most patients realize: type 2 diabetes, obstructive sleep apnea, hypertension, dyslipidemia, and established cardiovascular disease.

Two are frequently undiagnosed. Sleep apnea is common with obesity and now has an approved drug indication — tirzepatide (Zepbound) is the first medication FDA-approved for OSA, which makes a sleep study genuinely worth pursuing. Cardiovascular disease opens a separate route, since injectable semaglutide demonstrated a 20% reduction in major adverse cardiovascular events in SELECT and the oral formulation carries a CV indication.

Expect a Denial and Plan the Appeal

First-pass denials are common in this category and frequently overturned. Ask your prescriber whether their office has an appeals process and templates — many do, and the difference in approval rates between practices that appeal systematically and those that do not is substantial.

Also recheck annually. Formularies change every plan year in both directions, and employers have been actively adjusting: a Mercer study found employers pulled back on GLP-1 weight-loss coverage in 2026 with further cuts considered for 2027, while only 72% of those currently covering said they were likely to continue.

Questions Worth Asking Before You Enrol

• Which specific product does my formulary cover, for which indication?
• What comorbidities do I have documented, and which qualify?
• Have I been screened for sleep apnea?
• Does your office handle appeals, and what is your approval rate?
• When does my formulary change, and should I recheck?

A provider that answers these clearly is managing a treatment plan. One that deflects to a monthly price is selling a subscription.